404
Transcatheter Aortic Valve Replacement (TAVR) Market | 2023-2028
Transcatheter Aortic Valve Replacement (TAVR) Market Size, Share, Trends, Dynamics, Forecast, & Growth Analysis: 2023-2028
A Transcatheter aortic valve replacement (TAVR), also known as Transcatheter aortic valve implantation (TAVI) is a minimally invasive surgical process that treats the aortic valve by substituting a new biological valve into the old aortic valve’s place without removing the damaged valve. The TAVR method, which is relatively like a stent placed in an artery, is carried out by inserting a fully collapsible replacement valve into the aortic valve site with the help of a catheter.
The transcatheter aortic valve replacement (TAVR) market was estimated at USD 7.04 billion in 2022.
The transcatheter aortic valve replacement (TAVR) market is likely to reach USD 22.72 billion in 2028.
The transcatheter aortic valve replacement (TAVR) market is likely to grow at a CAGR of 21.19% during 2023-2028.
Medtronic plc (Ireland), Boston Scientific Corporation (The U.S), Meril Life Sciences Pvt. Ltd., Inc. (India), Edwards Lifesciences Corporation (The U.S), St. Jude Medical, Inc. (The U.S), JenaValve Technology, Inc. (The U.S), Bracco SpA (Italy), Transcatheter Technologies GmbH (Germany), Abbott (The U.S) and Symetis SA (Switzerland) are among the key players.
North America witnessed the largest share of the transcatheter aortic valve replacement market in 2022.
Transfemoral implantation dominated the transcatheter aortic valve replacement market in 2022.